4-acetyl-1-(1H-benzoimidazol-5-yl)-5-(benzo[c][1,2,5]thiadiazol-5-yl)-3-hydroxy-1,5-dihydro-pyrrol-2-one | 1024610-26-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻二唑类
• 英文名称: 4-acetyl-1-(1H-benzoimidazol-5-yl)-5-(benzo[c][1,2,5]thiadiazol-5-yl)-3-hydroxy-1,5-dihydro-pyrrol-2-one
• 英文别名: 4-Acetyl-1-(1H-benzoimidazol-5-yl)-5-benzo[c][1,2,5]thiadiazol-5-yl-3-hydroxy-1,5-dihydro-pyrrol-2-one；3-acetyl-1-(3H-benzimidazol-5-yl)-2-(2,1,3-benzothiadiazol-5-yl)-4-hydroxy-2H-pyrrol-5-one
• CAS: 1024610-26-1
• 化学式: C₁₉H₁₃N₅O₃S
• 分子量: 391.41
• InChiKey: NBHLZNDGSROZGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  140
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-acetyl-1-(1H-benzoimidazol-5-yl)-5-(benzo[c][1,2,5]thiadiazol-5-yl)-3-hydroxy-1,5-dihydro-pyrrol-2-one 、 甲基肼 在 溶剂黄146 作用下， 反应 4.0h， 以6.8 mg的产率得到5-(3H-benzimidazol-5-yl)-4-(2,1,3-benzothiadiazol-5-yl)-2,3-dimethyl-4H-pyrrolo[3,4-c]pyrazol-6-one
  参考文献：
  名称：

  WO2021009068A5

  摘要：

  公开号：

  WO2021009068A5
• 作为产物：
  描述：

  5-溴甲基-2,1,3-苯并噻重氮 在 manganese(IV) oxide 、 水 、 caesium carbonate 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 氯仿 为溶剂， 反应 17.0h， 生成 4-acetyl-1-(1H-benzoimidazol-5-yl)-5-(benzo[c][1,2,5]thiadiazol-5-yl)-3-hydroxy-1,5-dihydro-pyrrol-2-one
  参考文献：
  名称：

  WO2021009068A5

  摘要：

  公开号：

  WO2021009068A5

文献信息

• Novel Inhibitors of Glutaminyl Cyclase
  申请人：Thormann Michael

  公开号：US20090269301A1

  公开（公告）日：2009-10-29

  The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, R 1 represents heteroaryl, -carbocyclyl-heteroaryl, -alkenylheteroaryl or -alkylheteroaryl; R 2 represents hydrogen; halogen; alkenyl; alkynyl; -alkenylaryl; -alkenylheteroaryl; alkyl, which may optionally be substituted by one or more groups selected from halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl, halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; -alkylcarbocyclyl; -alkylheterocyclyl; aryl; heteroaryl; heterocyclyl; -alkylaryl; -alkyl(aryl) 2 , -alkylheteroaryl; -aryl-heteroaryl; -heterocyclyl-aryl; -aryl-aryl; -heteroaryl-aryl; -heteroaryl-heteroaryl, and —C(O)R 4 ; R 3 represents halogen; alkyl optionally substituted by one or more groups selected from halogen, hydroxyl, alkoxy, thioalkyl, —C(O)OH and —C(O)O-alkyl; aryl; heteroaryl; —C(O)R 5 ; R 4 and R 5 independently represent alkyl, aryl, heteroaryl, -alkylaryl, -alkylheteroaryl, carbocyclyl, heterocyclyl, -alkylcarbocyclyl and -alkylheterocyclyl, with the proviso that, when R 1 is imidazolyl, -carbocyclyl-imidazolyl, -alkenyl-imidazolyl or -alkyl-imidazolyl, then R 3 may not be —C(O)R 5 .

  本发明涉及式（I）化合物，其组合物和用于疾病治疗的用途。其中，R1代表杂环芳基，-碳环芳基-杂环芳基，-烯基杂环芳基或-烷基杂环芳基；R2代表氢，卤素，烯基，炔基，-烯基芳基，-烯基杂环芳基，烷基，可以选择被一个或多个从卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的烷基，可以选择被一个或多个从烷基，卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的碳环芳基，可以选择被一个或多个从烷基，卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的-烷基碳环芳基，-烷基杂环芳基，芳基，杂环芳基，杂环芳基，-烷基芳基2，-烷基杂环芳基，-芳基杂环芳基，-杂环芳基-芳基，-芳基-芳基，-杂环芳基-芳基，-杂环芳基-杂环芳基和-C（O）R4；R3代表卤素，烷基，可以选择被一个或多个从卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的烷基，芳基，杂环芳基和-C（O）R5；R4和R5独立地代表烷基，芳基，杂环芳基，-烷基芳基，-烷基杂环芳基，碳环芳基，杂环芳基，-烷基碳环芳基和-烷基杂环芳基，但当R1是咪唑基，-碳环芳基-咪唑基，-烯基咪唑基或-烷基咪唑基时，R3不能是-C（O）R5。
• Inhibitors of glutaminyl cyclase
  申请人：Probiodrug AG

  公开号：US08278345B2

  公开（公告）日：2012-10-02

  The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, R1 represents heteroaryl, -carbocyclyl-heteroaryl, -alkenylheteroaryl or -alkylheteroaryl; R2 represents hydrogen; halogen; alkenyl; alkynyl; -alkenylaryl; -alkenylheteroaryl; alkyl, which may optionally be substituted by one or more groups selected from halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl, halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; -alkylcarbocyclyl; -alkylheterocyclyl; aryl; heteroaryl; heterocyclyl; -alkylaryl; -alkyl(aryl)2, -alkylheteroaryl; -aryl-heteroaryl; -heterocyclyl-aryl; -aryl-aryl; -heteroaryl-aryl; -heteroaryl-heteroaryl, and —C(O)R4; R3 represents halogen; alkyl optionally substituted by one or more groups selected from halogen, hydroxyl, alkoxy, thioalkyl, —C(O)OH and —C(O)O-alkyl; aryl; heteroaryl; —C(O)R5; R4 and R5 independently represent alkyl, aryl, heteroaryl, -alkylaryl, -alkylheteroaryl, carbocyclyl, heterocyclyl, -alkylcarbocyclyl and -alkylheterocyclyl, with the proviso that, when R1 is imidazolyl, -carbocyclyl-imidazolyl, -alkenyl-imidazolyl or -alkyl-imidazolyl, then R3 may not be —C(O)R5.

  本发明涉及公式（I）化合物，其组合物和用于疾病治疗的用途，其中R1代表杂环芳基，-碳环芳基-杂环芳基，-烯基杂环芳基或-烷基杂环芳基；R2代表氢，卤素，烯基，炔基，-烯基芳基，-烯基杂环芳基，烷基，该烷基可以选择性地被一个或多个从卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代；碳环芳基，该碳环芳基可以选择性地被一个或多个从烷基，卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代；-烷基碳环芳基；-烷基杂环芳基；芳基；杂环芳基；杂环芳基；-烷基芳基2，-烷基杂环芳基；-芳基-杂环芳基；-杂环芳基-芳基；-芳基-芳基；-杂环芳基-芳基；-杂环芳基-杂环芳基，和-C（O）R4；R3代表卤素；烷基，该烷基可以选择性地被一个或多个从卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代；芳基；杂环芳基；-C（O）R5；R4和R5独立地表示烷基，芳基，杂环芳基，-烷基芳基，-烷基杂环芳基，碳环芳基，杂环芳基，-烷基碳环芳基和-烷基杂环芳基，但是当R1为咪唑基，-碳环芳基-咪唑基，-烯基咪唑基或-烷基咪唑基时，R3不能为-C（O）R5。
• WO2008/55945
  申请人：——

  公开号：——

  公开（公告）日：——
• 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES
  申请人：Probiodrug AG

  公开号：EP2089383A1

  公开（公告）日：2009-08-19
• US8278345B2
  申请人：——

  公开号：US8278345B2

  公开（公告）日：2012-10-02